^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

nivatrotamab (GD2xCD3)

i
Other names: humanized anti-GD2 x anti-CD3 bispecific antibody, GD2xCD3, Hu3F8-BsAb, Humanized 3F8 Bispecific Antibody
Associations
Trials
Company:
Memorial Sloan-Kettering Cancer Center, Y-mAbs Therap
Drug class:
CD3 agonist, GD2 ganglioside inhibitor
Related drugs:
Associations
Trials
over2years
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers (clinicaltrials.gov)
P1/2, N=11, Terminated, Y-mAbs Therapeutics | N=30 --> 11 | Trial completion date: Feb 2022 --> Oct 2021 | Recruiting --> Terminated | Trial primary completion date: Feb 2022 --> Oct 2021; study terminated due to business priorities
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
nivatrotamab (GD2xCD3)